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Abstract
Introduction: HLA-B*35 is associated with increased risk of developing pulmonary hypertension in SSc patients. We
previously reported that HLA-B*35 induces endothelial cell dysfunction via activation of ER stress/UPR and
upregulation of the inflammatory response. Because PBMCs from lcSSc-PAH patients are also characterized by
activation of ER stress/UPR and inflammation, the goal of this study was to assess whether the presence of
HLA-B*35 contributes to those characteristics.
Methods: PBMCs were purified from healthy controls (n = 49 HC) and lcSSc patients, (n = 44 with PAH, n = 53
without PAH). PBMCs from each group were stratified for the presence of HLA-B*35. Global changes in gene
expression in response to HLA-B*35, HLA-B*8 or empty lentivirus were investigated by microarray analysis in HC
PBMCs. Total RNA was extracted and qPCR was performed to measure gene expression.
Results: ER stress markers, in particular the chaperones BiP and DNAJB1 were significantly elevated in PBMC
samples carrying the HLA-B*35 allele. IL-6 expression was also significantly increased in HLA-B*35 lcSSc PBMCs and
positively correlated with ER stress markers. Likewise, HMGB1 was increased in HLA-B*35-positive lcSSc PBMCs.
Global gene expression analysis was used to further probe the role of HLA-B*35. Among genes downregulated by
HLA-B*35 lentivirus were genes related to complement (C1QB, C1QC), cell cycle (CDNK1A) and apoptosis (Bax,
Gadd45). Interestingly, complement genes (C1QC and C1QB) showed elevated expression in lcSSc without PAH, but
were expressed at the low levels in lcSSc-PAH. The presence of HLA-B*35 correlated with the decreased expression
of the complement genes. Furthermore, HLA-B*35 correlated with decreased expression of cyclin inhibitors (p21,
p57) and pro-apoptotic genes (Bax, Gadd45) in lcSSc B35 subjects. FYN, a tyrosine kinase involved in proliferation of
immune cells, was among the genes that were positively regulated by HLA-B*35. HLA-B*35 correlated with
increased levels of FYN in lcSSc PBMCs.
Conclusions: Our study demonstrates that HLA-B*35 contributes to the dysregulated expression of selected ER
stress, inflammation and proliferation related genes in lcSSc patient PBMCs, as well as healthy individuals, thus
supporting a pathogenic role of HLA-B*35 in the development of PAH in SSc patients.
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Introduction
The contribution of genetic factors to the development of
systemic sclerosis (SSc, Scleroderma) is well documented
[1]. Genetic studies showed a higher incidence of SSc in
families with a history of disease compared to the general
population (1.5–1.7 % vs 0.026 %). Also, family studies re-
vealed that the relative risk of developing SSc in first-
degree relatives of affected individuals is higher than in
third-degree relatives [2]. The susceptibility loci within the
MHC (major histocompatibility complex) region consist-
ently showed strong association with SSc in different co-
horts and were confirmed in a large-scale genome-wide
association study (GWAS) [3]. Of particular interest is
HLA-B*35 (human leukocyte antigen class B), which was
shown to be associated with increased risk for developing
pulmonary arterial hypertension (PAH) in Italian SSc pa-
tients [4, 5]. This was confirmed in a study of Brazilian
SSc patients [6]. HLAB*35 was also associated with SSc in
a Choctaw Indian tribe with increased prevalence of SSc
[7]. Furthermore, the association between HLA-B*35 and
various other disorders as well as severe viral infections
has been reported [6–9]. In particular, studies in patients
with HIV (human immunodeficiency virus) infection from
different geographical areas have shown a correlation be-
tween HLA-B*35 phenotype and progression of AIDS
(Acquired Immune Deficiency Syndrome) [10–12].
We have previously observed that the presence of HLA-
B*35 contributes to endothelial cell dysfunction by signifi-
cantly increasing production of endothelin-1 (ET-1) and
significantly decreasing endothelial nitric oxide synthase
(eNOS) in conjunction with the upregulation of endoplas-
mic reticulum (ER) stress and unfolded protein response
(UPR) in cultured endothelial cells (ECs) [13, 14]. Further-
more, HLA-B*35-dependent activation of ER stress/UPR
correlated with upregulation of the interferon-regulated
genes and other inflammatory genes, including IL-6.
A subsequent study using peripheral blood mononuclear
cells (PBMCs) obtained from limited cutaneous systemic
sclerosis (lcSSc) patients also demonstrated elevated levels
of several ER stress markers, particularly in lcSSc patients
with PAH. A positive correlation between selected ER
stress/UPR markers (BiP/GRP78, glucose regulated protein,
and DNAJB1) and IL-6 was also observed, suggesting that
ER stress/UPR may have a role in the altered function of
circulating immune cells in patients with lcSSc [15].
Given the association of the HLA-B*35 with the ER stress
and UPR in endothelial cells, in this study, we examined in
greater detail the potential contribution of HLA-B*35 to
the dysregulated pathways in lcSSc lymphocytes.
Materials and methods
Study participants
The study subjects consisted of the patients described in
our previous study [15, 16], as well as additional healthy
controls and lcSSc patients (described in Additional
file 1: Table S1). The Boston University Medical Center
Institutional Review Board (Boston, MA, USA) reviewed
and approved the conduct of this study. Informed consent
was obtained from all patients and healthy subjects. Sub-
jects included 97 patients with lcSSc according to diagnos-
tic [17] and subtype criteria [18] (44 with PAH and 53
without PAH), as well as 49 normal healthy controls.
Patients with lcSSc were stratified into those with or with-
out PAH based on echocardiography or right heart
catheterization (RHC); in all patients designated as PAH (n
= 44), the diagnosis was confirmed by RHC (mean pulmon-
ary arterial pressure (mPAP) ≥ 25 mm Hg, pulmonary capil-
lary wedge pressure (PCWP) ≤15 and a pulmonary vascular
resistance (PVR) ≥3 Wood units), or with PCWP> 15, but ≤
18 considered to have PAH if adjudicated by the attending
pulmonologist on the basis of PVR, PAd-PCWP gradient
and trans-pulmonary gradient (and were enrolled in the RE-
VEAL Registry as patients with PAH). Patients were consid-
ered not to have PAH if echocardiography demonstrated a
pulmonary artery systolic pressure <35 mm Hg and normal
right ventricular size and function. The modified Rodnan
skin score (mRSS) was determined for each patient on the
day of the PBMC collection [19].
SSc disease duration was measured from the onset of
the first non–Raynaud’s phenomenon symptom of SSc.
The mean ± SD disease duration in lcSSc patients was
10 ± 9 years. The mean ± SD age in lcSSc patients was
58 ± 9 years (80 % were women and 45 % had PAH).
The mean age for the healthy controls (HCs) was 44 ±
18 years (21 of the 49 HCs were under 30 years old),
and 43 % were women.
Peripheral blood mononuclear cell isolation
Blood was collected from healthy controls and patients in
CPTTM tubes designed for one-step cell separation (Becton
Dickinson, Mountain View, CA, USA). The sample was
then immediately mixed and centrifuged at 1,800 RCF at
ambient temperature for 30 min. The PBMC cell layer was
then transferred to a 15 ml tube, and PBMCs were washed
twice with PBS and lysed in RNeasy RLT buffer (Qiagen,
Valencia, CA, USA).
Lentiviral infection of PBMCs
A lentiviral vector expressing HLA-B*35 (or HLA-B*8) was
generated by Applied Biological Materials Inc (Richmond,
BC, Canada). Briefly, the cDNA encoding HLAB*35/B*8
was cloned in the shuttle vector pLenti-II-HA-CMV, which
contains a HIS tag driven by a separate CMV promoter,
and was used to generate recombinant lentiviruses. Lenti-
virus pLenti-II-HA-CMV was used as a control vector.
Healthy control PBMCs were plated in six-well plates at a
density of 0.8-1x106 cells/well in RPMI supplemented with
10 % FCS and 1 % AA overnight prior to transduction.
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Transductions were performed using M.O.I.’s ranging from
0.1 to 1 mixing the appropriate volume of virus with 8 mg/
ml Polybrene (Sigma, St. Louis, MO, USA), and adding the
mixture to the cells together with RPMI to achieve a total
volume of 500 μL per well. After 5–6 h incubation at 37 °C
an additional 500 μL of complete RPMI was added, cells
were centrifuged for 30 min at 1200 rpm and culture
medium was aspirated and replaced by fresh RPMI. The
transduced cells were collected after 72 h. Total RNA was
extracted using Qiagen’s RNeasy Mini Kits according to the
manufacturer’s protocol.
Microarray data analysis
The RNA quality and yield were assessed with an Agilent
2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) and a
NanoDrop Technologies ND-1000 Spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA). All micro-
array experiments were performed in one batch. Two hun-
dred nanograms of total RNA were amplified and purified
using a TotalPrep RNA Amplification Kit (Applied Biosys-
tems/Ambion, Foster City, CA, USA). The amplified com-
plementary DNA was hybridized on Illumina HT-12 arrays,
and the data were extracted with Illumina Genome studio
software. Pathway analysis was performed using BRB-
ArrayTools (National Cancer Institute, USA). Over-
represented Biocarta pathways were identified using Efron-
Tibshirani’s GSA test p <0.005. Efron-Tibshirani’s test uses
‘maxmean’ statistics to identify gene sets differentially
expressed. All heatmaps show unsupervised hierarchical
analysis results (data have been submitted to Gene Expres-
sion Omnibus (GEO) public repository, accession number
GSE73355).
Quantitative real-time PCR
Real-time RT-PCR was performed using IQTM SYBR
Green Supermix (BioRad, Waltham, MA, USA and MyiQ™
Single-Color Real-Time PCR Detection System (BioRad,
Waltham, MA, USA). The amount of template used in the
PCR reactions was cDNA corresponding to 200 ng reverse-
transcribed total RNA. DNA polymerase was first activated
at 95 °C for 3 min, denatured at 95 °C for 30 s, and
annealed/extended at 61 °C for 30 s, for 40 cycles according
to the manufacturer’s protocol. Expression of the house-
keeping genes β-actin, GADPH, and 18S served as internal
positive controls in each assay performed. After measure-
ment of the relative fluorescence intensity for each sample,
the amount of each mRNA transcript was expressed as a
threshold cycle (c(t)) value. The primer sequences are avail-
able upon request.
Statistical analysis
Comparisons of RT-PCR expression were analyzed using
Mann–Whitney non-parametric analyses. Correlations were
calculated using Spearman non-parametric correlations.
Results
The presence of HLA-B*35 allele exacerbates activation of
selected ER stress/UPR genes in lcSSc PBMCs
The study subjects (lcSSc with PAH and without PAH), as
well as healthy controls (HC) were stratified for the pres-
ence of HLA-B*35 allele (18 % of the HCs and 27 % of the
lcSSc were B35-positive, of those 27 % of PAH and 26 %
of NoPAH patients were B35-positive). We examined the
correlation between the presence of HLA-B*35 and the
expression of ER stress markers, focusing on the genes
previously shown to be elevated in lcSSc-PAH PBMCs
[15]. Among the previously tested ER stress markers, the
chaperones BiP and DNAJB1 were consistently elevated in
PBMC samples carrying the HLA-B*35 allele compared to
samples negative for HLA-B*35. BiP was elevated in both
B35-positive healthy controls (p < 0.05) and in B35-
positive lcSSc patients (p < 0.05) (Fig. 1, upper panel).
Likewise, DNAJB1 was expressed at higher levels in B35-
positive HCs (p < 0.01) and B35-positive lcSSc patients
(p < 0.0001). Furthermore, the highest levels of BiP and
DNAJB1 were present in B35-positive lcSSc-PAH samples
(BiP, p < 0.05 lcSSc-PAH B35+ vs lcSSc-PAH B35-;
DNAJB1 p < 0.005 lcSSc-PAH B35+ vs lcSSc-PAH B35-)
(Fig. 1, lower panel). Among the other UPR genes associ-
ated with lcSSc, only ATF4 (activating transcription factor
4) was elevated in B35-positive lcSSc vs B35-negative
lcSSc (p < 0.0005), but these differences were not seen in
HC samples (Fig. 1, right panel). These results suggest that
the HLA-B*35 allele may primarily influence the expres-
sion of chaperons, such as BiP and DNAJ in PBMCs. Not-
ably, a significantly increased expression of the ER stress
genes was also observed in comparisons of HC B35- and
lcSSc B35- samples. This suggests that besides HLA-B*35
other stressful conditions such as inflammation, infection
or oxidative stress may contribute to elevated ER stress
and UPR gene expression.
Global gene expression analysis after transduction of
HLA-B*35
Microarray analyses were used to further understand
the role of HLA-B*35 allele. Lentivirus vector was used
to ectopically express HLA-B*35 or HLA-B*8 (another
antigen of class I, not known to be associated with an
increased risk for developing PAH in patients with
lcSSc). PBMCs were isolated from healthy controls and
transduced with lentiviruses (empty lentivirus served as
an additional control). The basal expression levels of a
number of genes were significantly changed in re-
sponse to lentivirus carrying B35 compared to B8 (or
control).
Sixty-four pathways were over-represented in HLA-
B*35 vs. HLA-B*8 comparison (List of pathways in
Additional file 2: Table S2). Among the upregulated path-
ways were heat shock proteins (BiP, DNAJB1), eicosanoid
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metabolism (ALOXA5P, arachidonate 5-lipoxygenase-
activating protein), kinases (FYN, ATM), and inflam-
mation (HMGB1, high-mobility group protein B1).
Genes with decreased expression levels were related
to the cell cycle pathway (inhibitor CDNK1A, cyclin-
dependent kinase inhibitor 1A), the apoptotic pathway
(Bax and Gadd45, growth arrest and DNA-damage-
inducible 45), and the complement pathway (C1QB
and C1QC, complement component 1, q subcompo-
nent, C and B chain) (Fig. 2). Genes that showed the
most pronounced changes in the array were further
confirmed in PBMC cell lines isolated from four
different HCs transduced with lentivirus carrying
HLA-B*35 (B8 and control virus) by qPCR (Additional
file 3: Figure S1). Interestingly, one of our top hits,
ALOX5P, was not consistently changed in the trans-
duced HCs used for verification and was not further
investigated.
The presence of HLA-B*35 allele in PBMCs enhances
inflammation
We have previously reported that interleukin 6 (IL-6)
mRNA levels were significantly elevated in lcSSc vs
healthy control PBMCs, with the highest levels in lcSSc-
PAH PBMCs [15]. When HC and lcSSc PBMCs were
stratified based on the presence of the HLA-B*35 allele,
IL-6 was expressed at a higher level in HLA-B*35-
positive PBMCs. The association between HLA-B*35 and
higher IL-6 was observed in lcSSc PBMCs obtained from
patients with and without PAH, but not in healthy con-
trols (Fig. 3, upper panel). We have previously noted a
positive correlation (r = 0.53, p < 0.0001) between mRNA
expression of IL-6 and BiP in PBMC samples from pa-
tients with lcSSc [15]. Notably, IL-6 expression was also
associated with the presence of HLA-B*35. When lcSSc
PBMC samples were stratified based on the presence of
HLA-B*35 allele, the correlation between IL-6 and BiP
Fig. 1 HLA-B*35 correlates with higher expression of selected ER stress/UPR genes. PBMCs were isolated from HC (n = 49), lcSSc (n = 97, NoPAH
n = 53 and PAH n = 44), and grouped according to the presence of the HLA-B*35 allele: HC B35+ (n =9), HC B35- (n = 40); lcSSc B35+ (n =26),
lcSSc B35- (n =71); lcSSc NoPAH B35+ (n =14), lcSSc NoPAH B35- (n = 39), lcSSc PAH B35+ (n = 12) and lcSSc PAH B35- (n = 32). mRNA levels of
BiP (left panel), DNAJB1 (middle panel), and ATF4 (right panel) were measured by qPCR. Expression of the housekeeping genes β-actin, GADPH,
and 18S served as internal positive controls. Data are expressed as the fold-change normalized to mRNA expression in a single HC sample. Each
data point represents a single subject; horizontal lines show the mean. ER endoplasmic reticulum, PBMCs peripheral blood mononuclear cells,
HC healthy controls, lcSSc limited cutaneous systemic sclerosis, PAH pulmonary arterial hypertension, ATF4 activating transcription factor 4
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was higher in B35-positive samples compared to B35-
negative samples (r = 0.36 vs r = 0.26).
The array analysis identified an injury response alar-
min family member, HMGB1 upregulated in the pres-
ence of HLA-B*35. HMGB1 was elevated in lcSSc
PBMCs vs HC PBMCs (p < 0.0001). Furthermore, the ex-
pression level of HMGB1 was elevated in B35-positive
HC (p < 0.05) and lcSSc (p < 0.0001) samples. However,
no differences were observed between lcSSc-NoPAH and
lcSSc-PAH PBMCs or in the further stratification for the
presence of antigen HLA-B*35 (Fig. 3, lower panel).
These results suggest that HLA-B*35 may influence the
expression of selected inflammatory genes.
Complement genes are downregulated in HLA-B*35-positive
lcSSc PBMCs
Complement complexes are part of the innate immune
system and their activation is known to be involved in
the pathogenesis of systemic autoimmune diseases [20].
Complement genes, C1QC and C1QB, were downregu-
lated in HC PBMCs transduced with lentivirus B35.
Interestingly, both genes were elevated in PBMCs from
lcSSc patients without PAH, but were expressed at sig-
nificantly lower levels in lcSSc-PAH samples when
compared to NoPAH samples (p < 0.005) (Fig. 4). Fur-
ther stratification for the presence of B35 revealed that
HLA-B*35 correlated with the low levels of the comple-
ment genes, with the lowest levels observed in B35-
positive lcSSc-PAH samples (lcSSc PAH B35+ vs lcSSc
PAH B35-, p < 0.01).
HLA-B*35 correlates with low expression of cell cycle
inhibitors and pro-apoptotic genes
Healthy subject PBMCs transduced with the HLA-B*35
lentivirus showed downregulation of the genes related
to growth arrest and apoptosis (p21, p57, BAX,
Gadd45). Analysis of patient PBMCs also showed sig-
nificantly lower levels of the cyclin-dependent kinase
(CDK) inhibitors, p21 and p57, in B35-positive lcSSc
PBMCs compared to B35-negative lcSSc (p < 0.01 and
p < 0.001, respectively) (Fig. 5a). Healthy controls showed
significantly decreased p21, but not p57, in B35-
positive samples. Further stratification for the pres-
ence of HLA-B*35 in lcSSc revealed no difference in
lcSSc-NoPAH B35- vs lcSSc-NoPAH B35+ while mod-
erately lower levels were observed in lcSSc-PAH B35-
positive compared to lcSSc-PAH B35-negative samples
(Additional file 4: Figure S2).
Fig. 2 Heatmap showing the expression of gene clusters. PBMCs were isolated from healthy control and transduced with 0.1-0.5-1 MOI of
lentivirus encoding HLA-B*35, HLA-B*8, or control lentivirus for 72 h. The global changes in gene expression were investigated by Illumina HT-12
arrays (Illumina Inc, San Diego, CA, USA). Among genes downregulated by HLA-B*35 lentivirus compared to HLA-B*8, we observed genes related
to complement (C1QB, C1QC), cell cycle (CDNK1A), and apoptotic (Bax, Gadd45) pathways. Genes with increased expression levels were related to
proliferation (FYN, ATM), inflammation (HMGB1), and ER stress/UPR (HSPA1A and DNAJB1). Expression values above the mean are indicated in dark
blue, those below the mean are indicated in light blue. PBMCs, peripheral blood mononuclear cells, MOI multiplicity of infection, ER endoplasmic
reticulum, UPR unfolded protein response
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Pro-apoptotic genes, such as Bax and Gadd45, were
also downregulated in HLA-B*35 positive samples ob-
tained from HC and lcSSc subjects (Fig. 5b). Low levels
were also observed in B35-positive lcSSc-NoPAH and
PAH samples (lcSSc PAH B35+ vs lcSSc PAH B35-, p <
0.05) (Additional file 4: Figure S2).
The above global gene expression analysis indicated
that two proliferation-associated genes, FYN tyrosine
kinase and ATM serine/threonine kinase, are upregu-
lated in HLA-B*35 transduced PBMCs. Accordingly, the
levels of FYN were elevated in B35-positive HCs (p <
0.05) and B35-positive lcSSc samples (p<0.005) (Fig. 5c).
Interestingly, FYN levels were lower in lcSSc-PAH vs
lcSSc-NoPAH but elevated in B35-positive subjects in
both subpopulations (Additional file 4: Figure S2). In
contrast to the microarray results, ATM was expressed
at lower levels in B35-positive HCs, but its expression
did not differ in B35-positive and B35-negative lcSSc
samples (Fig. 5c). Also, no differences were observed be-
tween lcSScNoPAH and PAH, but further stratification
for the presence of HLA-B*35 revealed slightly increased
levels in lcSSc-NoPAH B35+ vs lcSSc-NoPAH B35- and
slightly decreased levels in lcSSc-PAH B35+ vs lcSSc-
NoPAH B35- (Additional file 4: Figure S2). These results
suggested that the presence of HLA-B*35 may influence
apoptotic and proliferative responses in PBMC
subpopulations.
Discussion
This study explored the potential contribution of HLA-
B*35 to the immune dysregulation in lcSSc. An unbiased
approach based on the microarrays from the human
PBMCs transduced with the HLA-B*35 carrying lentivirus
revealed a number of genes modulated in response to
HLA-B*35. Selected genes were then verified in PBMCs
obtained from patients with lcSSc as well as healthy con-
trols. Among the genes that significantly correlated with
the presence of HLA-B*35 in PBMCs were the heat shock
proteins, inflammatory genes, complement genes, and
genes related to cell growth and apoptosis. The upregula-
tion of heat shock proteins typically occurs in response to
various stressful conditions, including inflammation, in-
fection, and various environmental toxins. In particular,
the HSP group, which includes BiP (HSPA5) and its co-
chaperone DNAJ (HSP40), is required for protein folding
and is highly expressed during ER stress [21]. Notably,
higher levels of heat shock proteins were also present in
PBMCs obtained from healthy individuals carrying the
Fig. 3 IL-6 and HMGB1 are elevated in B35-positive subjects. PBMCs were isolated from HC (n = 49), lcSSc (n = 97, NoPAH n = 53 and PAH n = 44) and
grouped according to the presence of the HLA-B*35 allele: HC B35+ (n = 9), HC B35- (n = 40); lcSSc B35+ (n =26), lcSSc B35- (n =71); lcSSc NoPAH B35+
(n =14), lcSSc NoPAH B35- (n = 39), lcSSc PAH B35+ (n = 12) and lcSSc PAH B35- (n = 32). mRNA levels of IL-6 (top panel) and HMGB1 (bottom panel)
were determined by qPCR. Expression of the housekeeping genes β-actin, GADPH, and 18S served as internal positive controls. Data are expressed as
the fold-change normalized to mRNA expression in a single HC sample. Each data point represents a single subject; horizontal lines show the mean.
Right top panel depicts linear regression analysis of the relationship between expression of BiP and IL-6 in PBMCs from lcSSc B35-negative and B35-
positive patients. IL-6 interleukin-6, HMGB1 high-mobility group protein B1, PBMCs, peripheral blood mononuclear cells, HC healthy controls, lcSSc limited
cutaneous systemic sclerosis, PAH pulmonary arterial hypertension
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HLA-B*35 allele, supporting the view that genetic factors
could contribute to the increased levels of ER stress at
least in a restricted population of SSc patients.
Inflammation and, in particular, elevated levels of IL-6
have been linked to the development of PAH [22]. Recent
studies have suggested that blocking IL-6 improves both




study, increased levels of IL-6 in HLA-B*35-positive
lcSSc PBMCs suggests that this is a genetic risk factor
leading to enhanced sensitivity of HLA-B*35 leukocytes
to activation. Further, our observation that the highest
IL-6 levels and the highest expression of ER stress
markers, BiP and HSP40, are found in B35-positive
lcSSc-PAH samples, suggests that this relationship be-
tween ER stress and IL-6 plays a key role in the devel-
opment of lcSSc-PAH.
Notably, we also found higher levels of HGMB1 in both
HLA-B*35-positive lcSSc subjects and healthy controls.
Serum levels of HGMB1 were previously shown to be ele-
vated in SSc [23]. HMGB1, as well as HSPs, are part of the
alarmin family, the endogenous molecules constitutively
available and released after injury. Alarmins can promote
activation of innate immune cells, recruitment and activa-
tion of antigen-presenting cells for host defense and tissue
repair through activation of TLRs (Toll-like receptors)
[24]. Thus, elevated HGMB1 may represent another im-
portant mediator of the effect of HLA-B*35 on immune
dysregulation in lcSSc patients. Previous studies have
identified altered expression levels of several additional
Fig. 4 Expression of selected complement genes is decreased in HLA-B*35 positive lcSSc PBMCs. PBMCs were isolated from HC (n = 49), lcSSc
(n = 82, NoPAH n = 43 and PAH n = 39) and grouped according to the presence of the HLA-B*35 allele: HC B35+ (n =9), HC B35- (n = 40); lcSSc
NoPAH B35+ (n =14), lcSSc NoPAH B35- (n = 29), lcSSc PAH B35+ (n = 12) and lcSSc PAH B35- (n = 27). mRNA levels of C1QC and C1QB were
measured by qPCR. Expression of the housekeeping genes β-actin, GADPH and 18S served as internal positive controls in each assay performed.
lcSSc limited cutaneous systemic sclerosis, PBMCs peripheral blood mononuclear cells, PAH pulmonary arterial hypertension, HC healthy controls,
qPCR quantitative polymerase chain reaction
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inflammatory mediators in lcSSc PBMCs, including
MCP1, IL-13, and IL-7R [25–27]. However, the presence
of HLA-B35 had no effect on the expression of those
genes (Lenna, unpublished results).
Among the HLA-B*35-regulated genes related to the
immune system were the complement genes, C1QB and
C1QC. Both genes were moderately elevated in lcSSc
subjects without PAH in comparison to healthy controls;
however, their expression was significantly reduced in
lcSSc-PAH samples. HLA-B*35-transduced PBMCs had
reduced levels of C1Q genes and this finding was verified
in PBMCs from healthy controls as well as lcSSc samples
with and without PAH. Complement is part of the innate
immune system and its major function is to recognize and
Fig. 5 HLA-B*35 is associated with low levels of selected cyclin inhibitors and pro-apoptotic genes in lcSSc PBMCs. PBMCs were isolated from HC
(n = 49), lcSSc (n = 81) and grouped according to the presence of the HLA-B*35 allele: HC B35+ (n = 9), HC B35- (n = 40); lcSSc B35+ (n = 25) and
lcSSc B35- (n = 56). mRNA levels of p21, p57 a, Bax, Gadd45 b and FYN, ATM c were measured by qPCR. Expression of the housekeeping genes
β-actin, GADPH, and 18S served as internal positive control in each assay performed. lcSSc limited cutaneous systemic sclerosis, PBMCs peripheral
blood mononuclear cells, HC healthy controls
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eliminate pathogens. In particular, formation of immune
complexes is one of the principal ways of activating the
classical pathway of the complement system. If the com-
plement system fails in this function, waste material can
accumulate and evoke an autoimmune response. Genetic
deficiency of C1Q is a strong risk factor for development
of SLE (systemic lupus erythematosus), triggering pro-
inflammatory mediators, such as C5a and C3, and im-
paired cytokine production resulting in persistent and
recurrent viral infections, known to be an exacerbating
factor for SLE [28–31], but much less is known about the
role of complement in SSc. The biological significance of
the reduced levels of C1Q in carriers of the HLA-B*35
allele remains to be clarified.
Lastly, we found significantly decreased levels of se-
lected cyclin inhibitors and pro-apoptotic genes in HLA-
B*35-positive PBMCs obtained from lcSSc patients and
healthy controls. On the other hand, expression of a
tyrosine-protein kinase FYN was upregulated in HLA-
B*35 positive PBMCs. FYN plays a role in many bio-
logical processes including regulation of cell growth and
survival [32, 33]. It participates in the downstream sig-
naling pathways that lead to T-cell differentiation and
proliferation following T-cell receptor (TCR) stimula-
tion. These results suggest that the presence of HLA-
B*35 may favor proliferation of the immune cells and
thus contribute to the increased inflammatory response.
However, more studies are needed to fully appreciate the
functional significance of the presence of HLA-B*35 al-
lele in patients with SSc.
Conclusions
In summary, the current study further extends our pre-
vious findings on the role of HLA-B*35 in endothelial
cells [14]. In both cell types HLA-B*35 induced ER stress
and inflammation related genes. Importantly, the current
study verified these experimental findings in cells ob-
tained from lcSSc patients. Notably, the presence of
HLA-B*35 correlated with increased levels of alarmins,
including HSPs and HMGB1, in healthy individuals, in-
dicating that the presence of HLA-B*35 induces a stress
response and is likely to sensitize endothelial and im-
mune cells to further stressful conditions. While some of
the biological consequences of HLA-B*35, including
modulation of the complement and apoptotic responses,
requires further investigation, this study supports the
pathological role of HLA-B*35 in SSc.
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Additional file 3: Figure S1. Validation of array results in HC PBMCs
transduced with lentivirus. Expression levels of selected genes
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and downregulated (CDKNA1, known as p21, Bax, Gadd45, C1QC, and
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selected cyclin inhibitors and pro-apoptotic genes in lcSSc PBMCs. PBMCs
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n = 38) and grouped according to the presence of the HLA-B*35 allele: HC
B35+ (n = 9), HC B35- (n = 40); lcSSc NoPAH B35+ (n = 14), lcSSc NoPAH
B35- (n = 29), lcSSc PAH B35+ (n = 12) and lcSSc PAH B35- (n = 26). mRNA
levels of p21, p57 (a), Bax, Gadd45 (b), and FYN, ATM (c) were measured by
qPCR. Expression of the housekeeping genes β-actin, GADPH and 18S
served as internal controls in each assay performed. (TIF 1.63 mb)
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